Handel Black Diamond Therapeutics, Inc. - BDTX CFD
Føj til favorit- Opsummering
- Historisk Data
- Begivenheder
- Resultatopgørelse
- Saldo
- Cash flow
- Ejerskab
Handelsbetingelser
| Spænd | 0.0672 | ||||||||
|
Long position, gebyr natten over
Long position overnight fee
Gå til platform | -0.025457% | ||||||||
|
Short position, gebyr natten over
Short position overnight fee
Gå til platform | 0.003235% | ||||||||
| Gebyr natten over, tid | 21:00 (UTC) | ||||||||
| Min. handlet mængde | 1 | ||||||||
| Valuta | USD | ||||||||
| Margen | 20% | ||||||||
| Aktiebørs | United States of America | ||||||||
| Kommission på handel | 0% |
*Information provided by Capital.com
Black Diamond Therapeutics Inc ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Nøglestatistikker
| Tidligere luk* | 2.3266 |
| Åben* | 2.3465 |
| 1-Års Ændring* | 33.32% |
| Dagens Spænd* | 2.3465 - 2.4963 |
| 52-Ugers Spænd | 1.18-4.08 |
| Gennemsnitlig Volumen (10 dage) | 74.14K |
| Gennemsnitlig Volumen (3 måneder) | 1.74M |
| Market Cap | 85.44M |
| P/E-forhold | -100.00K |
| Udestående aktier | 36.51M |
| Omsætning | N/A |
| EPS | -2.38 |
| Dividend (Udbytte %) | N/A |
| Beta | 1.89 |
| Næste indtjeningsopgørelse | Aug 7, 2023 |
Al data kommer fra Refinitiv, med undtagelse af data markeret med en asterisk, som er *data fra Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Luk | Change | Change (%) | Åben | High | Low |
|---|---|---|---|---|---|---|
| Jun 5, 2023 | 2.4564 | 0.1998 | 8.85% | 2.2566 | 2.5063 | 2.2366 |
| Jun 2, 2023 | 2.3266 | 0.1399 | 6.40% | 2.1867 | 2.3665 | 2.0969 |
| Jun 1, 2023 | 2.1368 | 0.3295 | 18.23% | 1.8073 | 2.1668 | 1.7973 |
| May 31, 2023 | 1.8373 | 0.0300 | 1.66% | 1.8073 | 1.8572 | 1.7973 |
| May 30, 2023 | 1.8572 | 0.0999 | 5.68% | 1.7573 | 1.8772 | 1.7573 |
| May 26, 2023 | 1.7673 | 0.0699 | 4.12% | 1.6974 | 1.7774 | 1.6575 |
| May 25, 2023 | 1.7274 | 0.0699 | 4.22% | 1.6575 | 1.7574 | 1.6575 |
| May 24, 2023 | 1.6974 | 0.0100 | 0.59% | 1.6874 | 1.7374 | 1.6375 |
| May 23, 2023 | 1.6775 | -0.1298 | -7.18% | 1.8073 | 1.8672 | 1.6774 |
| May 22, 2023 | 1.8373 | 0.0899 | 5.14% | 1.7474 | 1.8772 | 1.7474 |
| May 19, 2023 | 1.7773 | 0.0699 | 4.09% | 1.7074 | 1.7873 | 1.6175 |
| May 18, 2023 | 1.5976 | -0.0998 | -5.88% | 1.6974 | 1.6975 | 1.5576 |
| May 17, 2023 | 1.7074 | -0.0400 | -2.29% | 1.7474 | 1.7674 | 1.6774 |
| May 16, 2023 | 1.7673 | -0.1198 | -6.35% | 1.8871 | 1.9171 | 1.7673 |
| May 15, 2023 | 1.9171 | 0.1198 | 6.67% | 1.7973 | 1.9271 | 1.7573 |
| May 12, 2023 | 1.8672 | -0.0399 | -2.09% | 1.9071 | 1.9071 | 1.8073 |
| May 11, 2023 | 1.9171 | 0.1098 | 6.08% | 1.8073 | 1.9970 | 1.7973 |
| May 10, 2023 | 1.8472 | 0.0499 | 2.78% | 1.7973 | 1.8972 | 1.7973 |
| May 9, 2023 | 1.8173 | 0.0400 | 2.25% | 1.7773 | 1.8173 | 1.6575 |
| May 8, 2023 | 1.9072 | 0.0300 | 1.60% | 1.8772 | 1.9371 | 1.8572 |
Black Diamond Therapeutics, Inc. Events
| Tid (UTC) (UTC) | Land | Begivenhed |
|---|---|---|
| Friday, June 9, 2023 | ||
| Tid (UTC) (UTC) 16:45 | Land US
| Begivenhed Black Diamond Therapeutics Inc at Jefferies Healthcare Conference Black Diamond Therapeutics Inc at Jefferies Healthcare ConferenceForecast -Previous - |
| Monday, August 7, 2023 | ||
| Tid (UTC) (UTC) 12:30 | Land US
| Begivenhed Q2 2023 Black Diamond Therapeutics Inc Earnings Release Q2 2023 Black Diamond Therapeutics Inc Earnings ReleaseForecast -Previous - |
| Monday, November 6, 2023 | ||
| Tid (UTC) (UTC) 13:30 | Land US
| Begivenhed Q3 2023 Black Diamond Therapeutics Inc Earnings Release Q3 2023 Black Diamond Therapeutics Inc Earnings ReleaseForecast -Previous - |
- Årlig
- Pr kvartal
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total omsætning | 0 | 0 | 0 | 0 | 0 |
| Totale Driftsudgifter | 92.828 | 126.872 | 69.57 | 29.332 | 8.904 |
| Salgs/Generelle/Admin. Udgifter, Total | 28.391 | 30.043 | 21.361 | 7.579 | 1.954 |
| Forskning & Udvikling | 64.437 | 96.829 | 48.209 | 21.753 | 6.95 |
| Usædvanlig Udgift (Indkomst) | 0 | ||||
| Driftsindtægter | -92.828 | -126.872 | -69.57 | -29.332 | -8.904 |
| Renteindkomst (Udgift), Netto Ikke-Drift | -0.219 | 3.464 | 4.041 | -5.932 | -0.011 |
| Andre, Netto | -0.354 | -2.188 | -1.725 | 0.006 | -0.016 |
| Netto Indkomst Før Skat | -91.169 | -125.596 | -67.254 | -35.258 | -8.931 |
| Netto Indkomst Efter Skat | -91.169 | -125.596 | -67.254 | -35.258 | -8.931 |
| Netto Indkomst Før Ekstra Ting | -91.169 | -125.596 | -67.254 | -35.258 | -8.931 |
| Netto Indkomst | -91.169 | -125.596 | -67.254 | -35.258 | -8.931 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -91.169 | -125.596 | -67.254 | -35.258 | -8.931 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -91.169 | -125.596 | -67.254 | -35.258 | -8.931 |
| Fortyndet Netto Indkomst | -91.169 | -125.596 | -67.254 | -35.258 | -8.931 |
| Fortyndet Vægtet Gennemsnit Aktier | 36.3256 | 36.189 | 32.9071 | 32.6364 | 32.6364 |
| Fortyndet EPS Uden Ekstraordinære Ting | -2.50977 | -3.47056 | -2.04375 | -1.08033 | -0.27365 |
| Dividends per Share - Common Stock Primary Issue | 0 | ||||
| Fortyndet Normaliseret EPS | -2.57122 | -3.47056 | -2.04375 | -1.08033 | -0.27365 |
| Gain (Loss) on Sale of Assets | 2.232 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Total omsætning | 0 | 0 | 0 | 0 | 0 |
| Totale Driftsudgifter | 21.561 | 21.852 | 22.124 | 23.173 | 25.679 |
| Salgs/Generelle/Admin. Udgifter, Total | 6.808 | 7.243 | 6.277 | 6.978 | 7.893 |
| Forskning & Udvikling | 14.753 | 14.609 | 15.847 | 16.195 | 17.786 |
| Driftsindtægter | -21.561 | -21.852 | -22.124 | -23.173 | -25.679 |
| Renteindkomst (Udgift), Netto Ikke-Drift | 0.622 | -1.573 | 0.562 | 0.386 | 0.406 |
| Andre, Netto | 0.064 | 0.115 | -0.092 | -0.143 | -0.234 |
| Netto Indkomst Før Skat | -20.875 | -21.078 | -21.654 | -22.93 | -25.507 |
| Netto Indkomst Efter Skat | -20.875 | -21.078 | -21.654 | -22.93 | -25.507 |
| Netto Indkomst Før Ekstra Ting | -20.875 | -21.078 | -21.654 | -22.93 | -25.507 |
| Netto Indkomst | -20.875 | -21.078 | -21.654 | -22.93 | -25.507 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -20.875 | -21.078 | -21.654 | -22.93 | -25.507 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -20.875 | -21.078 | -21.654 | -22.93 | -25.507 |
| Fortyndet Netto Indkomst | -20.875 | -21.078 | -21.654 | -22.93 | -25.507 |
| Fortyndet Vægtet Gennemsnit Aktier | 36.4839 | 36.3902 | 36.3462 | 36.2939 | 36.2713 |
| Fortyndet EPS Uden Ekstraordinære Ting | -0.57217 | -0.57922 | -0.59577 | -0.63179 | -0.70323 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Fortyndet Normaliseret EPS | -0.57217 | -0.64056 | -0.59577 | -0.63179 | -0.70323 |
| Gain (Loss) on Sale of Assets | 2.232 |
- Årlig
- Pr kvartal
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Totale Nuværende Aktiver | 127.706 | 215.703 | 319.554 | 155.714 | 51.684 |
| Likvider og Kortsigtede Investeringer | 122.807 | 209.786 | 315.067 | 154.666 | 51.66 |
| Likvider & Lignende | 34.315 | 65.799 | 34.605 | 154.666 | 51.66 |
| Prepaid Expenses | 4.899 | 5.917 | 4.487 | 1.048 | 0.024 |
| Total Assets | 156.255 | 247.682 | 329.67 | 158.295 | 51.826 |
| Property/Plant/Equipment, Total - Net | 27.381 | 30.74 | 8.787 | 0.164 | 0.134 |
| Property/Plant/Equipment, Total - Gross | 28.131 | 31.109 | 8.951 | 0.276 | 0.234 |
| Accumulated Depreciation, Total | -0.75 | -0.369 | -0.164 | -0.112 | -0.1 |
| Other Long Term Assets, Total | 1.168 | 1.239 | 1.329 | 2.417 | 0.008 |
| Total Current Liabilities | 15.261 | 23.642 | 14.218 | 4.863 | 2.575 |
| Accounts Payable | 1.877 | 4.107 | 2.538 | 1.964 | 0.416 |
| Accrued Expenses | 13.384 | 19.535 | 11.68 | 2.899 | 0.452 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 0 | 1.707 | |||
| Total Liabilities | 40.56 | 51.782 | 21.912 | 4.879 | 6.598 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 25.299 | 28.14 | 7.694 | 0.016 | 4.023 |
| Total Equity | 115.695 | 195.9 | 307.758 | 153.416 | 45.228 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 60.77 | ||
| Common Stock | 0.005 | 0.005 | 0.005 | 0.001 | 0.001 |
| Additional Paid-In Capital | 452.503 | 440.129 | 425.363 | 3.812 | 0.169 |
| Retained Earnings (Accumulated Deficit) | -334.989 | -243.82 | -118.224 | -50.97 | -15.712 |
| Total Liabilities & Shareholders’ Equity | 156.255 | 247.682 | 329.67 | 158.295 | 51.826 |
| Total Common Shares Outstanding | 36.4343 | 36.2346 | 36.0784 | 32.6364 | 32.6364 |
| Redeemable Preferred Stock | 0 | 0 | 200.573 | ||
| Kortsigtede Investeringer | 88.492 | 143.987 | 280.462 | ||
| Other Equity, Total | -0.414 | 0.614 | |||
| Unrealized Gain (Loss) | -1.824 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Totale Nuværende Aktiver | 107.977 | 127.706 | 150.978 | 168.558 | 188.304 |
| Likvider og Kortsigtede Investeringer | 103.366 | 122.807 | 144.181 | 160.89 | 179.739 |
| Likvider & Lignende | 39.141 | 34.315 | 53.96 | 55.877 | 54.081 |
| Kortsigtede Investeringer | 64.225 | 88.492 | 90.221 | 105.013 | 125.658 |
| Prepaid Expenses | 4.611 | 4.899 | 6.797 | 7.668 | 8.565 |
| Total Assets | 135.582 | 156.255 | 180.416 | 198.834 | 219.482 |
| Property/Plant/Equipment, Total - Net | 26.437 | 27.381 | 28.27 | 29.098 | 29.945 |
| Property/Plant/Equipment, Total - Gross | 27.282 | 28.131 | 28.98 | 29.681 | 30.439 |
| Accumulated Depreciation, Total | -0.845 | -0.75 | -0.71 | -0.583 | -0.494 |
| Other Long Term Assets, Total | 1.168 | 1.168 | 1.168 | 1.178 | 1.233 |
| Total Current Liabilities | 12.847 | 15.261 | 21.143 | 19.706 | 19.469 |
| Accounts Payable | 3.046 | 1.877 | 5.76 | 2.222 | 1.883 |
| Accrued Expenses | 9.801 | 13.384 | 15.383 | 17.484 | 17.586 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 37.392 | 40.56 | 47.185 | 46.463 | 46.922 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 24.545 | 25.299 | 26.042 | 26.757 | 27.453 |
| Total Equity | 98.19 | 115.695 | 133.231 | 152.371 | 172.56 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | |
| Common Stock | 0.005 | 0.005 | 0.005 | 0.005 | 0.005 |
| Additional Paid-In Capital | 455.225 | 452.503 | 449.625 | 446.909 | 443.657 |
| Retained Earnings (Accumulated Deficit) | -355.864 | -334.989 | -313.911 | -292.257 | -269.327 |
| Other Equity, Total | -1.176 | -1.824 | -2.488 | -2.286 | -1.775 |
| Total Liabilities & Shareholders’ Equity | 135.582 | 156.255 | 180.416 | 198.834 | 219.482 |
| Total Common Shares Outstanding | 36.512 | 36.4343 | 36.3662 | 36.3157 | 36.2876 |
| Redeemable Preferred Stock |
- Årlig
- Pr kvartal
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Netto indkomst/Startlinje | -91.169 | -125.596 | -67.254 | -35.258 | -8.931 |
| Likvider Fra Driftsaktiviteter | -85.082 | -100.148 | -52.146 | -24.674 | -8.454 |
| Likvider Fra Driftsaktiviteter | 0.508 | 0.205 | 0.052 | 0.047 | 0.044 |
| Ikke-Likvide Ting | 15.48 | 18.223 | 10.014 | 10.074 | 0.079 |
| Ændringer i Driftskapital | -9.901 | 7.02 | 5.042 | 0.463 | 0.354 |
| Likvider fra Investeringsaktiviteter | 53.366 | 130.613 | -281.691 | -0.021 | -0.076 |
| Kapitaludgifter | -0.192 | -2.71 | -0.142 | -0.021 | -0.076 |
| Andre Investerings-Cash-Flow-Ting, Total | 53.558 | 133.323 | -281.549 | 0 | |
| Likvider fra Financieringsaktiviteter | 0.177 | 0.729 | 214.944 | 127.756 | 52.312 |
| Financiering af Cash-Flow-Ting | 0 | -1.743 | 0 | ||
| Udstedelse (Pensionering) af Aktier, Netto | 0.177 | 0.729 | 214.944 | 129.499 | 52.312 |
| Udstedelse (Pensionering) af Gæld, Netto | 0 | ||||
| Netto Ændring i Likviditet | -31.539 | 31.194 | -118.893 | 103.061 | 43.782 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -20.875 | -91.169 | -70.091 | -48.437 | -25.507 |
| Cash From Operating Activities | -20.031 | -85.082 | -63.143 | -46.667 | -28.6 |
| Cash From Operating Activities | 0.122 | 0.508 | 0.382 | 0.253 | 0.125 |
| Non-Cash Items | 3.507 | 15.48 | 11.804 | 8.366 | 4.293 |
| Changes in Working Capital | -2.785 | -9.901 | -5.238 | -6.849 | -7.511 |
| Cash From Investing Activities | 24.806 | 53.366 | 51.044 | 36.537 | 16.729 |
| Capital Expenditures | 0 | -0.192 | -0.192 | -0.2 | -0.007 |
| Other Investing Cash Flow Items, Total | 24.806 | 53.558 | 51.236 | 36.737 | 16.736 |
| Cash From Financing Activities | 0.051 | 0.177 | 0.205 | 0.153 | 0.153 |
| Issuance (Retirement) of Stock, Net | 0.051 | 0.177 | 0.205 | 0.153 | 0.153 |
| Net Change in Cash | 4.826 | -31.539 | -11.894 | -9.977 | -11.718 |
| Investornavn | Investortype | Procent udestående | Aktiebeholdning | Aktieændring | Beholdningsdato | IOmsætningsscore |
|---|---|---|---|---|---|---|
| Versant Ventures | Venture Capital | 17.6634 | 6449348 | 0 | 2023-03-15 | LOW |
| Bellevue Asset Management AG | Investment Advisor | 14.778 | 5395839 | -5000 | 2023-03-31 | LOW |
| New Enterprise Associates (NEA) | Venture Capital | 9.4454 | 3448757 | 0 | 2023-03-31 | LOW |
| RA Capital Management, LP | Hedge Fund | 7.0932 | 2589904 | 0 | 2023-03-31 | LOW |
| Boxer Capital, L.L.C. | Hedge Fund | 5.5183 | 2014858 | 0 | 2023-03-31 | LOW |
| Invus Public Equities Advisors, LLC | Investment Advisor | 4.5095 | 1646517 | 0 | 2023-03-31 | LOW |
| EcoR1 Capital, LLC | Hedge Fund | 3.2621 | 1191094 | 908963 | 2023-03-31 | LOW |
| Epstein (David M) | Individual Investor | 2.5703 | 938479 | 0 | 2023-03-15 | LOW |
| Millennium Management LLC | Hedge Fund | 2.1269 | 776594 | 252037 | 2023-03-31 | HIGH |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.0749 | 757585 | 0 | 2023-03-31 | LOW |
| Citadel Advisors LLC | Hedge Fund | 1.5276 | 557771 | -216027 | 2023-03-31 | HIGH |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 1.4344 | 523719 | -127676 | 2023-03-31 | LOW |
| Verition Fund Management LLC | Hedge Fund | 0.943 | 344307 | 344307 | 2023-03-31 | HIGH |
| Newtyn Management, LLC | Hedge Fund | 0.8397 | 306609 | -8391 | 2023-03-31 | MED |
| Two Sigma Investments, LP | Hedge Fund | 0.7769 | 283654 | -72510 | 2023-03-31 | HIGH |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.7406 | 270428 | 5138 | 2023-03-31 | LOW |
| Renaissance Technologies LLC | Hedge Fund | 0.5957 | 217500 | -3113 | 2023-03-31 | HIGH |
| BlackRock Financial Management, Inc. | Investment Advisor/Hedge Fund | 0.5023 | 183398 | -102283 | 2023-03-31 | LOW |
| BioImpact Capital LLC | Investment Advisor/Hedge Fund | 0.3968 | 144888 | 0 | 2023-03-31 | LOW |
| Tekla Capital Management LLC | Investment Advisor | 0.3615 | 131990 | 0 | 2023-03-31 | LOW |
Hvorfor vælge Capital.com? Vores tal taler for sig selv.
Capital.com Group535K+
Handlende
87K+
Månedlkige, aktive klienter
$113M+
Månedlig investeringsvolumen
$64M+
Hævet hver måned
Handelslommeregner
Udregn dit hypotetiske P&L hvis du havde åbnet en CFD-handel på en given dato (vælg en dato) og lukket den på en anden dato (vælg en dato).
Handelskurtage
0
- 1:1
Gearing
1:1
- 20
- 100
- 500
- 1000
- 10000
Investering
Handelsstørrelse (Gearing x Investering):
Åben
Luk
Short Long
Black Diamond Therapeutics, Inc. Company profile
Om Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. er en virksomhed inden for onkologisk præcisionsmedicin. Virksomheden er fokuseret på opdagelse og udvikling af små molekylære MasterKey-behandlinger. Virksomheden opbygger en pipeline af små molekylære kinasehæmmere, der er rettet mod en række drivermutationer i kræft. Virksomhedens teknologiplatform, Mutation-Allostery-Pharmacology (MAP) platform, er designet til at gøre det muligt at analysere genetiske sekventeringsdata på populationsniveau for at opdage onkogene mutationer, der fremmer kræft på tværs af tumortyper. Dens førende produktkandidat, BDTX-189, er udviklet som en oralt tilgængelig, irreversibel lille molekylinhibitor, der er rettet mod et spektrum af 48 ikke-kanoniske og kanoniske drivermutationer i ErbB-kinaserne epidermal vækstfaktorreceptor (EGFR) og HER2. BDTX-1535 er en hjernepenetrerende inhibitor, der er rettet mod et spektrum af EGFR-mutationer, herunder allosteriske og kanoniske mutationer. Det har også programmer på et tidligt stadie, såsom B-Raf Proto-Oncogene (BRAF) og fibroblast growth factor receptor (FGFR).
| Industry: | Bio Therapeutic Drugs |
One Main Street, 14th Floor
CAMBRIDGE
MASSACHUSETTS 02142
US
Resultatopgørelse
- Annual
- Quarterly
Folk ser også
Leder du stadig efter en mægler, du kan stole på?
Deltag sammen med 535.000+ handlende over hele verden, der valgte at handle hos Capital.com